The ketogenic diet in children 3 years of age or younger

a 10-year single-center experience

Se Hee Kim, Alexandra Shaw, Robyn Blackford, Wesley Lowman, Linda C Laux, John J Millichap*, Douglas R. Nordli

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

The ketogenic diet (KD) is an effective treatment option for intractable epilepsy. Here, we reviewed the last 10 years of our experience with the KD and characterized its use in patients under 3 years of age. Medical records of all patients under the age of 3 years who were treated with the ketogenic diet from April 2004 to June 2014 were retrospectively reviewed. One hundred and nine patients with drug-resistant epilepsy were included. The mean age at the initiation of the KD was 1.4 ± 0.8 years old. The youngest patient was 3 weeks old. After 3 months, 39% (42/109) of patients responded to the KD and experienced more than 50% seizure reduction. Of those 42 patients, 20 (18%) achieved complete seizure control. Patients with a genetic etiology showed a better response to the KD in seizure reduction than the other patients (p = 0.03). Age at initiation of the KD was not related to eventual seizure outcome (p = 0.6). The KD continues to be an effective, safe, and well tolerated treatment option for infants with intractable epilepsy.

Original languageEnglish (US)
Article number8736
JournalScientific reports
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Ketogenic Diet
Seizures
Medical Records

ASJC Scopus subject areas

  • General

Cite this

Kim, Se Hee ; Shaw, Alexandra ; Blackford, Robyn ; Lowman, Wesley ; Laux, Linda C ; Millichap, John J ; Nordli, Douglas R. / The ketogenic diet in children 3 years of age or younger : a 10-year single-center experience. In: Scientific reports. 2019 ; Vol. 9, No. 1.
@article{15d8787ad0e041508461517782e72f11,
title = "The ketogenic diet in children 3 years of age or younger: a 10-year single-center experience",
abstract = "The ketogenic diet (KD) is an effective treatment option for intractable epilepsy. Here, we reviewed the last 10 years of our experience with the KD and characterized its use in patients under 3 years of age. Medical records of all patients under the age of 3 years who were treated with the ketogenic diet from April 2004 to June 2014 were retrospectively reviewed. One hundred and nine patients with drug-resistant epilepsy were included. The mean age at the initiation of the KD was 1.4 ± 0.8 years old. The youngest patient was 3 weeks old. After 3 months, 39{\%} (42/109) of patients responded to the KD and experienced more than 50{\%} seizure reduction. Of those 42 patients, 20 (18{\%}) achieved complete seizure control. Patients with a genetic etiology showed a better response to the KD in seizure reduction than the other patients (p = 0.03). Age at initiation of the KD was not related to eventual seizure outcome (p = 0.6). The KD continues to be an effective, safe, and well tolerated treatment option for infants with intractable epilepsy.",
author = "Kim, {Se Hee} and Alexandra Shaw and Robyn Blackford and Wesley Lowman and Laux, {Linda C} and Millichap, {John J} and Nordli, {Douglas R.}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-45147-6",
language = "English (US)",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

The ketogenic diet in children 3 years of age or younger : a 10-year single-center experience. / Kim, Se Hee; Shaw, Alexandra; Blackford, Robyn; Lowman, Wesley; Laux, Linda C; Millichap, John J; Nordli, Douglas R.

In: Scientific reports, Vol. 9, No. 1, 8736, 01.12.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The ketogenic diet in children 3 years of age or younger

T2 - a 10-year single-center experience

AU - Kim, Se Hee

AU - Shaw, Alexandra

AU - Blackford, Robyn

AU - Lowman, Wesley

AU - Laux, Linda C

AU - Millichap, John J

AU - Nordli, Douglas R.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - The ketogenic diet (KD) is an effective treatment option for intractable epilepsy. Here, we reviewed the last 10 years of our experience with the KD and characterized its use in patients under 3 years of age. Medical records of all patients under the age of 3 years who were treated with the ketogenic diet from April 2004 to June 2014 were retrospectively reviewed. One hundred and nine patients with drug-resistant epilepsy were included. The mean age at the initiation of the KD was 1.4 ± 0.8 years old. The youngest patient was 3 weeks old. After 3 months, 39% (42/109) of patients responded to the KD and experienced more than 50% seizure reduction. Of those 42 patients, 20 (18%) achieved complete seizure control. Patients with a genetic etiology showed a better response to the KD in seizure reduction than the other patients (p = 0.03). Age at initiation of the KD was not related to eventual seizure outcome (p = 0.6). The KD continues to be an effective, safe, and well tolerated treatment option for infants with intractable epilepsy.

AB - The ketogenic diet (KD) is an effective treatment option for intractable epilepsy. Here, we reviewed the last 10 years of our experience with the KD and characterized its use in patients under 3 years of age. Medical records of all patients under the age of 3 years who were treated with the ketogenic diet from April 2004 to June 2014 were retrospectively reviewed. One hundred and nine patients with drug-resistant epilepsy were included. The mean age at the initiation of the KD was 1.4 ± 0.8 years old. The youngest patient was 3 weeks old. After 3 months, 39% (42/109) of patients responded to the KD and experienced more than 50% seizure reduction. Of those 42 patients, 20 (18%) achieved complete seizure control. Patients with a genetic etiology showed a better response to the KD in seizure reduction than the other patients (p = 0.03). Age at initiation of the KD was not related to eventual seizure outcome (p = 0.6). The KD continues to be an effective, safe, and well tolerated treatment option for infants with intractable epilepsy.

UR - http://www.scopus.com/inward/record.url?scp=85067819953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067819953&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-45147-6

DO - 10.1038/s41598-019-45147-6

M3 - Article

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 8736

ER -